"id","rationale","versionIdentifier","uuid:ID","instanceType"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","eb6ce58a-3ed1-4660-b90c-fa40c2ffa8f7","StudyVersion"
